Mesoblast Limited (Nasdaq: MESO) today announced that its licensee in Japan, JCR Pharmaceuticals Co. Ltd., has received notification that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE